Cargando…

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

Selinexor, an oral Selective Inhibitor of Nuclear Export, targets Exportin 1 (XPO1, also termed CRM1). Non‐clinical studies support combining selinexor with proteasome inhibitors (PIs) and corticosteroids to overcome resistance in relapsed/refractory multiple myeloma (RRMM). We conducted a phase I d...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakubowiak, Andrzej J., Jasielec, Jagoda K., Rosenbaum, Cara A., Cole, Craig E., Chari, Ajai, Mikhael, Joseph, Nam, Jennifer, McIver, Amanda, Severson, Erica, Stephens, Leonor A., Tinari, Kathryn, Rosebeck, Shaun, Zimmerman, Todd M., Hycner, Tyler, Turowski, Agata, Karrison, Theodore, Zonder, Jeffrey A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6772147/
https://www.ncbi.nlm.nih.gov/pubmed/31124580
http://dx.doi.org/10.1111/bjh.15969